Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

CD40 ligand - Celldex Therapeutics

Drug Profile

CD40 ligand - Celldex Therapeutics

Alternative Names: Avrend; CD40-L; rHuCD40 ligand; rHuCD40L

Latest Information Update: 04 May 2016

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Amgen
  • Developer Amgen; Celldex Therapeutics Inc
  • Class Recombinant proteins
  • Mechanism of Action B cell stimulants; CD40 ligand stimulants; Dendritic cell stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer
  • No development reported Immunological disorders
  • Discontinued Head and neck cancer; Non-Hodgkin's lymphoma; Renal cancer; Solid tumours; Viral infections

Most Recent Events

  • 20 Apr 2016 Preclinical trials in Cancer in USA (Parenteral)
  • 18 Mar 2016 Early research in Cancer in USA (Parenteral)
  • 10 Apr 2009 CD40 ligand licensed to Celldex Therapeutics worldwide
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top